USD 1.94
(-11.82%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | - USD | 0.0% |
2022 | - USD | 0.0% |
2021 | - USD | 0.0% |
2020 | - USD | 0.0% |
2019 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2023 FY | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2022 FY | - USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2022 Q3 | - USD | 0.0% |
2021 Q2 | - USD | 0.0% |
2021 FY | - USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 Q4 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2020 Q3 | - USD | 0.0% |
2020 FY | - USD | 0.0% |
2019 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AIM ImmunoTech Inc. | 160 Thousand USD | 100.0% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 100.0% |
Armata Pharmaceuticals, Inc. | -29.24 Million USD | 100.0% |
Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 100.0% |
Azitra, Inc. | 260.45 Thousand USD | 100.0% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | 100.0% |
Chromocell Therapeutics Corporation | -2.57 Million USD | 100.0% |
Calidi Biotherapeutics, Inc. | -1.25 Million USD | 100.0% |
CEL-SCI Corporation | -3.95 Million USD | 100.0% |
iBio, Inc. | -1.02 Million USD | 100.0% |
Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 100.0% |
Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 100.0% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 100.0% |
NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 100.0% |
NanoViricides, Inc. | -759.01 Thousand USD | 100.0% |
Oragenics, Inc. | -15.45 Million USD | 100.0% |
BiomX Inc. | -1.22 Million USD | 100.0% |
BiomX Inc. | -1.22 Million USD | 100.0% |
Protalix BioTherapeutics, Inc. | 42.51 Million USD | 100.0% |
Palatin Technologies, Inc. | 4.39 Million USD | 100.0% |
Scorpius Holdings, Inc. | -2.21 Million USD | 100.0% |